FIGURE 2 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling

Mechanism of αEGFR-E-P125A action on inhibition of VM in the transcriptome. A, As previously shown, genes along the IL6-JAK-STAT3 signaling pathway are significantly upregulated from 2D to 3D using GSEA enrichment plot (left), with top upregulated genes along pathway depicted on the heat map (right). B, Genes along the IL6-JAK-STAT3 signaling pathway are significantly downregulated from 3D to the 3D αEGFR-E-P125A treatment transition using GSEA (left), with top downregulated genes depicted on the heat map (right). C, NanoString validation of RNA-seq data demonstrates that many JAK-STAT3 signaling genes are upregulated from 2D to 3D (left) and then downregulated upon αEGFR-E-P125A treatment (right). D, Integrated Pathview plot derived from KEGG database demonstrates upregulation of specific genes of interest within the JAK-STAT3 signaling pathway from the 2D to 3D transition. E, Pathview plot demonstrates overall inverse downregulation of JAK-STAT3 signaling pathway from the 3D-to-3D αEGFR-E-P125A treatment transition. F, As shown previously, genes along the Angiogenesis signaling pathway are significantly upregulated from 2D to 3D using GSEA enrichment plot (left), with top upregulated genes along pathway depicted on the heat map (right). G, Genes along the angiogenesis signaling pathway are significantly downregulated from 3D to the 3D αEGFR-E-P125A treatment transition using GSEA (left), with top downregulated genes depicted on the heat map (right). H, NanoString validation of RNA-seq data demonstrates that many angiogenesis signaling genes are upregulated from 2D to 3D (left) and then downregulated upon αEGFR-E-P125A treatment (right). I, Integrated SBGNview plot derived from Panther database demonstrates upregulation of genes of interest within the angiogenesis signaling pathway from 2D to 3D. J, SBGNview plot demonstrates overall downregulation of the angiogenesis signaling pathway upon 3D to αEGFR-E-P125A treatment transition.